Honeysuckle flower flavone liposome membrane, preparation method thereof and application of honeysuckle flower flavone liposome membrane in MRSA (Methicillin-Resistant Staphylococcus Aureus) resistance

By loading honeysuckle flavonoid liposomes on a mixed membrane material of chitosan and polyvinyl alcohol to form honeysuckle flavonoid liposome membrane, and using it in combination with vancomycin, the problem of resistance to traditional anti-MRSA drugs is solved, and the problem of drug resistance is achieved. Effective inhibition of MRSA and cell membrane destruction have improved the stability and antibacterial effect of the drug.

CN118903011APending Publication Date: 2024-11-08THE 958TH ARMY HOSPITAL OF THE CHINESE PEOPLES LIBERATION ARMY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410928496.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-11
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The resistance of existing anti-MRSA drugs has increased year by year, resulting in huge challenges in the treatment of MRSA infection. Traditional liposomes are prone to aggregation and unstable, making it difficult to effectively inhibit MRSA growth and biofilm formation.

Method used

Honeysuckle flavonoid liposomes were prepared using phospholipids and cholesterol as carriers, and loaded them into a mixed membrane of chitosan and polyvinyl alcohol to form a honeysuckle flavonoid liposome membrane (LFLM) to improve the stability of the drug and antibacterial Active and used in combination with vancomycin to enhance antibacterial effects.

Benefits of technology

The prepared honeysuckle flavonoid liposome membrane (LFLM) has significant anti-MRSA activity, can inhibit the growth, survival and biofilm formation of MRSA, promote cell wall and cell membrane destruction, reduce drug-resistant protein PBP2a and its regulatory gene expression, and improve MRSA. Sensitivity to antibacterial drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004938943780000061
    Figure BDA0004938943780000061
  • Figure BDA0004938943780000071
    Figure BDA0004938943780000071
  • Figure HDA0004938943800000011
    Figure HDA0004938943800000011
Patent Text Reader

Abstract

The invention discloses a honeysuckle flower flavone liposome membrane and a preparation method thereof, the honeysuckle flower flavone liposome membrane is prepared by taking phospholipid and cholesterol as carriers to obtain honeysuckle flower flavone liposome LFL, and then the LFL is loaded in a mixed membrane material of chitosan and polyvinyl alcohol to obtain the honeysuckle flower flavone liposome membrane LFLM. The invention further discloses application of the honeysuckle flavone liposome membrane LFLM in preparation of a medicine for resisting methicillin-resistant staphylococcus aureus. The prepared LFLM is good in drug release characteristic and has remarkable anti-MRSA activity, and the mechanism of the LFLM is possibly related to promotion of cell wall and cell membrane damage and inhibition of drug-resistant protein PBP2a and regulatory gene expression thereof. The invention provides a new treatment strategy for MRSA infection of skin and soft tissue.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biomedicine, and in particular to a honeysuckle flavone liposome membrane and a preparation method thereof and application thereof in resisting MRSA. Background Art

[0002] With the widespread use of broad-spectrum antibiotics, the bacterial resistance rate has been increasing year by year, and multidrug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) have emerged, posing a huge challenge to clinical anti-infection treatment. MRSA has been widely prevalent around the world since its discovery, and has become the main cause of bacteremia, endocarditis, skin and soft tissue infections, bone and joint infections, and hospital-acquired infections. At present, the first choice for the treatment of MRSA infection in clinical practice is vancomycin (VAN), followed by linezolid and daptomycin. However, in recent years, it has been found that the minimum inhibitory concentration of VAN for MRSA has drifted upward, and isolates resistant to the above antibiotics have also been found. Therefore, actively exploring new anti-MRSA methods is of great significance for clinical anti-infection treatment.

[0003] Honeysuckle is the dried buds or flowers of the honeysuckle plant of the Caprifoliaceae family. According to traditional Chinese medicine theory, it has the effects of clearing away heat and detoxifying, dispersing wind and dissipating heat. It is an important medicine for treating carbuncle, furuncle, throat paralysis, erysipelas, dysentery caused by heat toxins, and fever caused by febrile diseases. Modern pharmacological studies have shown that honeysuckle has multiple activities such as antibacterial, antiviral, antioxidant, anti-inflammatory, and immune regulation. Studies on the pharmacological substances of honeysuckle show that honeysuckle contains active substances such as volatile oils, organic acids, flavonoids, triterpenes and their saponins, among which chlorogenic acid and flavonoid compounds are its main antibacterial active ingredients. Studies have shown that the antibacterial effect of flavonoid components is stronger than that of chlorogenic acid.

[0004] As a new drug delivery system, liposomes have good encapsulation capacity for both hydrophilic and lipophilic drugs due to their amphiphilicity, can improve the stability of drugs, and have good biocompatibility. However, liposomes in liquid state have the disadvantages of easy aggregation and merging, drug leakage, and easy flow and loss during use. Films are solid preparations with good biocompatibility and adhesion, and are particularly suitable for skin administration. Loading liposomes on films can effectively improve their instability. Summary of the invention

[0005] The present invention studies the preparation of LF liposome membrane (LFLM) from Lonicerae Japonicae Flos flavonoids (LF) and studies its antibacterial effect and mechanism against MRSA. Based on this, the present invention provides the following technical solutions:

[0006] The first aspect of the present invention provides a method for preparing a honeysuckle flavonoid liposome membrane, comprising the following steps: preparing a honeysuckle flavonoid liposome LFL using phospholipids and cholesterol as carriers, and then loading the LFL into a mixed membrane material of chitosan and polyvinyl alcohol to prepare a honeysuckle flavonoid liposome membrane LFLM.

[0007] Preferably, the preparation method uses phospholipids and cholesterol as carriers and utilizes an organic solvent injection method to prepare the honeysuckle flavonoid liposomes LFL.

[0008] Preferably, the preparation method comprises the following steps:

[0009] S1. Preparation of Honeysuckle Flavonoid Liposomes LFL

[0010] Dissolve honeysuckle flavonoids LF in water to obtain an LF aqueous solution, dissolve soybean lecithin and cholesterol in an organic solvent and mix well, inject the organic solvent solution of soybean lecithin and cholesterol into the LF aqueous solution, stir to evaporate the organic solvent, and then ultrasonically break to obtain LF liposomes; the organic solvent is ethanol or ether;

[0011] S2. Take polyvinyl alcohol (PVA) dissolved in water, add glacial acetic acid and mix well, add chitosan CS and fully dissolve to form a PVA-CS solution. The proportion of each substance used is: PVA: CS: glacial acetic acid: water is 1.5-5 g: 0.3-1 g: 0.4-0.6 mL: 50 mL; LF liposomes, PVA-CS solution and glycerol are mixed in a volume ratio of 4-6: 3-5: 1, and then spread and dried to obtain LFLM; preferably, the proportion of each substance used is: PVA: CS: glacial acetic acid: water is 2-3 g: 0.3-0.7 g: 0.4-0.6 mL: 50 mL.

[0012] Preferably, in step S1, the concentration of the LF aqueous solution is 20-40 mg / mL, and it is preheated to 35-45° C.; the concentration of phospholipids in the organic solvent solution of soybean lecithin and cholesterol is 30-40 mg / mL, the mass ratio of phospholipids to cholesterol is 5-20, and preferably the mass ratio of phospholipids to cholesterol is 14-16. Under stirring conditions, the organic solvent solution of soybean lecithin and cholesterol is slowly injected into the LF aqueous solution with a syringe, wherein the mass ratio of LF to phospholipids is 4-6:1; after stirring to evaporate the organic solvent, the LF liposomes are obtained by ultrasonication with 30-50% ultrasonic energy for 8-20 minutes using an ultrasonic disruptor.

[0013] Preferably, in step S2, polyvinyl alcohol (PVA) is dissolved in hot water at 85-95° C., cooled to room temperature, glacial acetic acid is added and mixed, and chitosan (CS) is added and fully dissolved to form a PVA-CS solution.

[0014] Preferably, in step S2, the proportion of each substance used is: PVA:CS:glacial acetic acid:water is 2.5g:0.5g:0.5mL:50mL; LF liposomes, PVA-CS solution and glycerol are mixed in a volume ratio of 5:4:1.

[0015] The second aspect of the present invention provides a honeysuckle flavonoid liposome membrane, which is prepared by any of the preparation methods described above.

[0016] The third aspect of the present invention provides the use of the above-mentioned honeysuckle flavonoid liposome membrane LFLM in the preparation of drugs against methicillin-resistant Staphylococcus aureus.

[0017] Preferably, the application is the application of honeysuckle flavonoid liposome membrane LFLM in combination with VAN in the preparation of a drug for inhibiting methicillin-resistant Staphylococcus aureus MRSA;

[0018] Preferably, when LFLM and VAN are used together, the mass ratio of LFLM to VAN is 500-5000:1, more preferably 500-2000:1 or 800-1500:1.

[0019] In the above-mentioned application technical solution, LFLM or LFLM combined with VAN inhibits the growth, survival and biofilm formation of MRSA.

[0020] The beneficial effects of the present invention are:

[0021] The present invention uses phospholipids and cholesterol as carriers and uses an organic solvent injection method to prepare Lonicerae Japonicae Flos flavonoids liposomes (LFL), which are then loaded into a mixed membrane material of chitosan and polyvinyl alcohol to prepare LFLM, and the particle size, polydispersity index (PDI) and in vitro release rate of LFLM are measured. The antibacterial activity of LFLM against MRSA is evaluated by plate method and live-dead staining, the effect of LFLM on MRSA biofilm formation is observed by crystal violet staining, and the K of LFLM against MRSA is determined by microplate method. + Mg 2+, LDH, and AKP release were measured by qPCR. The effect of LFLM on MRSamecA and mecR1 mRNA levels was determined by qPCR. The affinity of representative compounds in honeysuckle flavonoids with PBP2a protein was evaluated by molecular docking.

[0022] The particle size of LFL prepared by the present invention is (80.91±3.96) nm, and the PDI value is (0.26±0.07); the release rate of LFLM within 12 hours is 55%, and the release rate within 36 hours is 73%; LFLM has a significant inhibitory effect on the growth, survival and biofilm formation of MRSA, and promotes its K + Mg 2+ , LDH, and AKP release, and reduced the levels of mecA and mecR1 mRNA; molecular docking showed that luteolin, rutin, luteolin, kaempferol, isorhamnetin, and quercetin in LF had good affinity with PBP2a.

[0023] The LFLM prepared by the present invention has good drug release characteristics and significant anti-MRSA activity, and its mechanism may be related to promoting cell wall and cell membrane destruction and inhibiting drug resistance protein PBP2a and its regulatory gene expression. The present invention provides a new treatment strategy for MRSA infection of skin and soft tissue. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 These are the particle size distribution diagram of LF liposome and the LFLM release curve: A. particle size distribution diagram of LF liposome; B. LFLM release curve.

[0025] Figure 2 The effects of LFLM on the growth and survival of MRSA: A. The effects of LFLM on MRSA colony formation; B. Histogram of colony formation in different groups; C. Representative graph of bacterial live and dead staining; D. Quantitative histogram of the ratio of dead bacteria to live bacteria in bacterial live and dead staining, magnification: 200×, scale bar: 100μm; *P<0.05, **P<0.01, ***P<0.001.

[0026] Figure 3 is the effect of LFLM on MRSA biofilm formation, *P<0.05, ***P<0.001.

[0027] Figure 4 is the K of LFLM against MRSA + Mg 2+ , LDH, and AKP release: A. LFLM on the K of MRSA + Effect of LFLM on the release of Mg from MRSA 2+C. Effect of LFLM on LDH activity of MRSA supernatant; D. Effect of LFLM on AKP activity of MRSA supernatant, **P<0.01, ***P<0.001.

[0028] Figure 5 The effects of LFLM on the mecA and mecR1 mRNA levels of MRSA: A. The effect of LFLM on the mecA mRNA level of MRSA; B. The effect of LFLM on the mecR1 mRNA level of MRSA, ***P<0.001.

[0029] Figure 6 These are the molecular docking results of representative flavonoid compounds in LF and PBP2a: A. Molecular docking binding energy heat map of representative flavonoid compounds in LF and PBP2a; B. Binding site pattern diagram of representative flavonoid compounds in LF and PBP2a. DETAILED DESCRIPTION

[0030] The present invention will be further described below in conjunction with embodiments, but the present invention is not limited thereto.

[0031] The experimental methods in the following examples are conventional methods unless otherwise specified.

[0032] Example 1

[0033] 1 Materials and methods

[0034] 1.1 Experimental Materials

[0035] Honeysuckle flavonoids (LF) were purchased from Xi'an Tianyi Biotechnology Co., Ltd.), vancomycin (VAN) was purchased from BioFroxx, Germany, soybean phospholipids (Soybean Phospholipid) were purchased from Avituo (Shanghai) Pharmaceutical Technology Co., Ltd., cholesterol was purchased from Beijing Dingguo Changsheng Biotechnology Co., Ltd., polyvinyl alcohol (PVA, alcoholysis degree 97.5-99.0mol%, viscosity 25.0-30.0mPa.s), chitosan (CS, viscosity 200-400mPa.s), and glycerol were purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., luteolin (content ≥98%) was purchased from China Food and Drug Inspection Institutes, acetonitrile (chromatographic grade) was purchased from Honeywell, USA, phosphoric acid (analytical grade) was purchased from Chengdu Kelong Chemical Reagent Factory, and anhydrous ethanol (analytical grade) was purchased from Chongqing Chuandong Chemical (Group) Co., Ltd. Company, phosphate buffered saline (PBS) was purchased from Shanghai Biyuntian Biotechnology Co., Ltd., MH broth and MH agar were purchased from Qingdao Haibo Biotechnology Co., Ltd., LIVE / DEADBcLight bacterial viability detection kit was purchased from Invitrogen, methicillin-resistant Staphylococcus aureus MRSA strain (ATCC43300) was purchased from Chongqing Enno Medical Equipment Co., Ltd., crystal violet stain was purchased from Beijing Solebow Technology Co., Ltd., potassium (K) assay kit, magnesium (Mg) test kit, lactate dehydrogenase (LDH) kit, alkaline phosphatase (AKP) assay kit were purchased from Nanjing Jiancheng Bioengineering Institute, total RNA extraction kit, reverse transcription kit, qPCR kit were purchased from Nanjing Novozyme Biotechnology Co., Ltd., and qPCR primers were synthesized by General Bio (Anhui) Co., Ltd.

[0036] 1.2 Experimental instruments

[0037] Laser particle size analyzer (ZetasizerNano-ZS90) was purchased from Malvern Instruments Ltd., UK; ultrasonic disruptor (Q500) was purchased from Gene Co., Ltd.; magnetic stirrer (MS-H-Pro+) was purchased from Dalong Xingchuang Experimental Instrument (Beijing) Co., Ltd.; low-temperature centrifuge (Allegra X-30R) was purchased from Beckman Coulter, USA; high performance liquid chromatograph (LC-M20A) was purchased from Shimadzu Corporation, Japan; constant temperature incubator shaker (THZ-300) and constant temperature incubator (GPH-9270N) were purchased from Shanghai Yiheng Technology Co., Ltd.; fluorescence microscope (DM4B) and its imaging system were purchased from Leica, Germany; multifunctional microplate reader (SYNERGY) was purchased from BioTek, USA; and fluorescence quantitative PCR instrument (CFX96) was purchased from BioRad, USA.

[0038] 1.3 Experimental methods

[0039] 1.3.1 Preparation of Honeysuckle Flavonoid Liposome Membrane (LFLM)

[0040] Weigh 900 mg LF and dissolve it in 30 mL pure water to make a 30 mg / mL solution, and place it on a magnetic stirrer and preheat it to 40 ° C. Weigh an appropriate amount of soybean lecithin and cholesterol and dissolve them in 5 mL of anhydrous ethanol to make the phospholipid concentration 35 mg / mL and the mass ratio of phospholipids to cholesterol 15, then slowly inject the anhydrous ethanol solution of soybean lecithin and cholesterol into the LF aqueous solution with a syringe under stirring at 500 r / min. After evaporating the ethanol under stirring, use an ultrasonic crusher to ultrasonicate at 40% ultrasonic energy for 10 minutes to obtain LF liposomes. Weigh 2.5 g PVA and dissolve it in 50 mL 90 ° C hot water, cool to room temperature and add 0.5 mL glacial acetic acid to mix, then add 0.5 g CS under stirring to completely dissolve it to form a PVA-CS solution. After mixing the LF liposomes, PVA-CS solution and glycerol in a volume ratio of 5:4:1, spread it on a flat glass plate and dry it to obtain LFLM.

[0041] 1.3.2 Determination of LF release rate in LFLM

[0042] 2mL of liquid LFLM was spread on a glass plate and dried to form a film. It was placed in a beaker containing 300mL of PBS solution, sealed with plastic wrap, and released on a constant temperature shaker at 150r / min and 37℃. 1mL of PBS was taken out at different time points and 1mL of new PBS was added. The content of luteolin in the taken PBS was determined by HPLC. The HPLC mobile phase was acetonitrile (A)-0.1% phosphoric acid solution (B); gradient elution (0-30min, 15%A→40%A); flow rate 1mL / min; injection volume 10μL; detection wavelength 254nm. The corresponding LF content was converted according to the percentage of luteolin in LF, and the release rate of LF was calculated. LF release rate = LF release amount / LF input amount × 100%.

[0043] 1.3.3 Inhibitory effect of LFLM on MRSA growth

[0044] MH broth medium was used to adjust the concentration of LFLM to 2.5, 5, and 10 mg / mL (based on LF concentration), and the concentration of VAN was adjusted to 10 μg / mL. A control group and a combined drug group (10 mg / mL LFLM and 10 μg / mL VAN) were set up. The concentration of MRSA was adjusted to OD 600 = 0.4, then diluted 10 4times, add one-tenth volume of MRSA bacterial solution to each group, mix well, take 60 μL and drop it into the center of MH agar plate, spread it with a spreader, place it in a 37℃ constant temperature incubator for 24 hours to observe the growth of colonies.

[0045] 1.3.4 Effect of LFLM on MRSA survival

[0046] According to the method in 1.3.3, adjust LFLM and VAN to the corresponding concentrations in MH broth medium in a 2 mL centrifuge tube. The volume of the solution is 1 mL, and then add 100 μL of OD 600 = 0.4 MRSA bacterial solution, placed on a constant temperature shaker at 150r / min and 37℃ for 6h. After the culture, centrifuge at 10000g for 10min and discard the supernatant, add 1mL of saline to resuspend the bacteria and centrifuge again to discard the supernatant, repeat the washing once, add 1.5μL of dye solution containing 5μM SYTO9 and 30μM PI, mix well, stain at room temperature and avoid light for 15min, take 10μL and drop it on the slide, seal the slide and collect images under a fluorescence microscope, green fluorescence shows live bacteria, red fluorescence shows dead bacteria. Use ImageJ software to calculate the area of ​​green fluorescence and red fluorescence areas, respectively, and calculate the ratio of dead bacteria to live bacteria.

[0047] 1.3.5 Effect of LFLM on MRSA biofilm formation

[0048] According to the method in 1.3.3, LFLM and VAN were adjusted to the corresponding concentrations in MH broth medium in a 2 mL centrifuge tube. The volume of the solution was 1 mL, and then 100 μL OD 600 = 0.4 MRSA bacterial solution was mixed and added to a 96-well plate, 100 μL per well. After culturing on a constant temperature shaker at 150 r / min and 37°C for 24 hours, the drug-containing bacterial solution was aspirated, and each well was rinsed twice with saline, and 100 μL of methanol was added to each well for 10 minutes. After discarding the methanol, the wells were rinsed twice with saline, and 0.5% crystal violet stain was added to stain at room temperature for 30 minutes. The stain was discarded and rinsed twice with saline, and 100 μL of 95% ethanol was added to dissolve it, and the OD was measured with an enzyme marker. 590 , and the biofilm inhibition rate was calculated according to the following formula: Biofilm inhibition rate (%) = (1-OD 测定 / OD 对照 )×100%.

[0049] 1.3.6 K of LFLM against MRSA + Mg 2+ , LDH, and AKP release

[0050] According to the method in 1.3.3, LFLM and VAN were adjusted to the corresponding concentrations using MH broth in a 2 mL centrifuge tube. The volume of the solution was 1 mL. 600 = 0.4 MRSA bacterial solution was diluted 100 times, 100 μL was added to each centrifuge tube and mixed, and then cultured on a constant temperature shaker at 150 r / min and 37°C for 24 h. After centrifugation at 10000 g for 10 min, the supernatant was taken and the K content in the supernatant was determined according to the instructions of the kit. + Mg 2+ , LDH, and AKP content.

[0051] 1.3.7 Effect of LFLM on mecA and mecR1 mRNA levels of MRSA

[0052] The drug concentration was adjusted according to the method in 1.3.6 and MRSA was intervened for 16 hours. The supernatant was then centrifuged and washed twice with saline to collect MRSA. Total RNA was extracted according to the kit instructions, and reverse transcription and qPCR amplification were performed. 16s rRNA was used as the internal reference gene. -△△t The relative mRNA levels of each group were calculated by qPCR. The qPCR primer sequences are shown in Table 1.

[0053] Table 1 qPCR primer sequences

[0054]

[0055]

[0056] 1.3.8 Molecular docking

[0057] In order to explore the affinity between the main active ingredients in LFLM and PBP2a, some flavonoid compounds with antibacterial activity reported in the literature were selected from honeysuckle and PBP2a protein for virtual molecular docking experiments. The PBP2a protein structure was downloaded from the PDB database and used as a receptor after dehydration, metal ion and hydrogenation treatment. The small molecule compound structure was downloaded from the PubChem database and used as a ligand after energy minimization. Semi-flexible molecular docking was performed using AutoDockVina, that is, the receptor protein structure was kept rigid and the small molecule compound ligand was flexible, and the site with the lowest binding energy was selected as the best binding site for visualization.

[0058] 1.4 Statistical analysis

[0059] The data obtained in the experiment were expressed as mean ± standard deviation and statistically analyzed using GraphPad Prism 8.0.1 software. After the data were tested for homogeneity of variance, one-way analysis of variance was used for comparison among multiple groups. P < 0.05 was considered statistically significant.

[0060] 2 Results

[0061] 2.1 LFLM characterization

[0062] Three batches of LF liposomes were prepared in parallel according to the ethanol injection method. The particle size was measured to be (80.91±3.96) nm and the PDI value was (0.26±0.07), indicating that the liposomes prepared by this method had a moderate and uniform particle size. The particle size distribution diagram is shown in Figure 1 A. The LFLM prepared by mixing LF liposomes with membrane materials can form a membrane smoothly and has good skin adhesion. The release experiment shows that LFLM is released quickly within 12 hours, with a total release rate of 55%. After 12 hours, the release rate slows down, and the cumulative release rate within 36 hours is 73%. The release curve is shown in Figure 1 B.

[0063] 2.2 Effects of LFLM on MRSA growth and survival

[0064] The results of the MH plate experiment showed that 5 and 10 mg / mL of LFLM had a certain inhibitory effect on the growth of MRSA, and the inhibitory effect of 10 mg / mL of LFLM combined with VAN on MRSA was better than that of LFLM or VAN alone (P<0.05). The results of bacterial live and dead staining showed that after LFLM or VAN intervention, the number of SYTO9-positive bacteria (live bacteria) decreased, and the number of PI-positive bacteria (dead bacteria) increased. The effect of the combined intervention of LFLM and VAN was better than that of LFLM or VAN alone (P<0.001). The above results show that LFLM can inhibit the growth of MRSA and promote its death. The results are shown in Figure 2 .

[0065] Effect of LFLM on MRSA biofilm formation

[0066] Crystal violet staining results showed that the staining of the LFLM intervention group was lighter and in a dose-dependent manner. The inhibition rate of 10 mg / mL LFLM on MRSA biofilm exceeded 80%, which was comparable to the effect of VAN. After the combined intervention of LFLM and VAN, the inhibition rate could reach 90%, which was better than that of LFLM or VAN alone, and the difference was statistically significant (P<0.05). Figure 3 .

[0067] 2.4 K of LFLM against MRSA + Mg 2+ , LDH, and AKP release

[0068] Bacterial AKP is mainly distributed between the cell wall and the cell membrane. When the cell wall is damaged, AKP can leak through the cell wall, while LDH is mainly distributed in the cytoplasm and can be released to the extracellular space when the cell membrane is damaged. +and Mg 2+ The leakage will also increase when the cell membrane is damaged. + Mg 2+ The levels of LDH and AKP can reflect the degree of damage to bacterial cell walls and cell membranes. The results showed that after LFLM or VAN intervention, K + and Mg 2+ The content of K in the supernatant was significantly increased, and the activities of LDH and AKP were also significantly increased, indicating that the cell wall and cell membrane of MRSA were damaged. After the combined intervention of LFLM and VAN, the K + Mg 2+ , LDH, and AKP levels further increased, with a statistically significant difference (P<0.001), indicating that the degree of injury has worsened. Figure 4 .

[0069] Effect of 2.5LFLM on mecA and mecR1 mRNA levels of MRSA

[0070] To further explore the effect of LFLM on the expression of MRSA resistance regulatory genes mecA and mecR1, the mRNA levels of mecA and mecR1 in each intervention group were detected by qPCR. Figure 5 As shown in the results, LFLM and VAN could significantly reduce the mRNA levels of mecA and mecR1. The effect of the combined intervention group of LFLM and VAN was better than that of the LFLM group, but there was no significant difference between the combined intervention group and the VAN group.

[0071] 2.6 Molecular docking results

[0072] Molecular docking results showed that luteolin, rutin, luteolin, kaempferol, isorhamnetin and quercetin in LF could spontaneously bind to PBP2a protein with binding energy ranging from -7.9 to -9.3 kcal / mol, and formed polar bonds with multiple amino acid residues of PBP2a protein with bond lengths of This suggests that these flavonoids have good affinity with PBP2a. Figure 6 .

[0073] 3 Analysis

[0074] Liposomes can encapsulate hydrophilic or hydrophobic drugs through their phospholipid bilayer membrane structure, thereby improving the water solubility and stability of the drugs. They also have high biocompatibility and biodegradability, making them ideal drug carriers. Common methods for preparing liposomes include thin film dispersion, ethanol injection, reverse evaporation, etc. The particle size usually obtained is between tens and hundreds of nanometers, which is conducive to the body's absorption. The ethanol injection method used in this study does not use toxic solvents, and has the advantages of simple operation, mild conditions, high liposome encapsulation rate, and uniform particle size. The disadvantage is that the preparation speed of this method is relatively slow, which is not conducive to large-scale preparation. CS is a natural animal polysaccharide with biodegradability, biocompatibility, non-toxicity, antibacterial, and immune-enhancing properties. Studies have shown that CS modification can not only improve the stability of liposomes but also enhance their antibacterial activity. PVA, as a non-toxic water-soluble polymer, has good biocompatibility and film-forming properties, and is often used as a basic film-forming material in pharmaceutical preparations and the food industry.

[15] In this study, CS was mixed with PVA and an appropriate amount of glycerol was added. After mixing with LF liposomes, the LFLM prepared was smooth and uniform with good toughness and adhesion.

[0075] Although VAN is used as the first-line drug for clinical anti-MRSA, with the widespread use of antimicrobial drugs, more and more VAN-resistant MRSA strains have been isolated worldwide. Therefore, multi-drug anti-MRSA regimens have gradually been developed based on VAN. Some studies have shown that the combination of flavonoid components of traditional Chinese medicine with antibiotics may be a promising strategy to combat MRSA. For example, baicalein enhances the therapeutic effect of VAN on fatal pneumonia caused by MRSA by inhibiting sortase A and caseinolytic enzyme P, and cypress biflavonoids reduce the virulence of MRSA by targeting caseinolytic protease P. This study preliminarily evaluated the antibacterial effect of LFLM and combined with VAN on MRSA through in vitro antibacterial experiments. The results showed that LFLM can significantly inhibit the growth of MRSA, promote its death, and increase its anti-MRSA activity after combining with VAN. Since bacterial biofilms can wrap bacteria inside to avoid damage from antibiotics and immune cells in the body, biofilms are an important cause of bacterial resistance, and inhibiting the formation of bacterial biofilms is an important way to prevent bacterial resistance. This study found that LFLM can inhibit the formation of MRSA biofilm, and the effect is better when combined with VAN. It can be seen that LFLM can be used as a potential anti-MRSA therapeutic drug.

[0076] The destruction of bacterial cell walls and cell membranes is the most common cause of their death. When bacterial cell walls and cell membranes are damaged, intracellular substances are easily leaked to the outside of the cell, leading to bacterial death. This study found that LFLM intervention can lead to K in MRSA culture fluid. + Mg 2+The levels of mecA and mecR1 were increased, and the activities of LDH and AKP were increased, indicating that the leakage of intracellular substances in MRSA increased, which may be related to the destruction of cell wall and cell membrane mediated by LFLM, which is consistent with previous research results. PBP2a encoded by the mecA gene is the main reason for the reduced sensitivity of MRSA to antimicrobial drugs, and mecR1 has a regulatory effect on the expression of mecA. Therefore, the production of PBP2a can be reduced by inhibiting the expression of mecA and mecR1 genes, thereby restoring the sensitivity of MRSA to antimicrobial drugs. The results of this study showed that LFLM can reduce the levels of mecA and mecR1 mRNA, which may help improve the sensitivity of MRSA to antimicrobial drugs. In addition, this study also preliminarily verified the affinity of representative components in LF with PBP2a through molecular docking technology. The results showed that all the flavonoids tested had good affinity with PBP2a, which provided support for LF to inhibit the activity of PBP2a.

[0077] In summary, this study loaded LF liposomes onto PVA-CS to prepare LFLM, which has good drug release properties and skin adhesion, and explored the antibacterial effect and mechanism of LFLM against MRSA through in vitro experiments. This study laid a foundation for the development of honeysuckle preparations and the research and development of new anti-MRSA drugs.

Claims

1. A method for preparing honeysuckle flavonoid liposome membrane, characterized in that: The method comprises the following steps: using phospholipid and cholesterol as carriers to prepare honeysuckle flavonoid liposome LFL, and then loading the LFL into a mixed membrane material of chitosan and polyvinyl alcohol to prepare honeysuckle flavonoid liposome membrane LFLM.

2. The preparation method according to claim 1, characterized in that: Honeysuckle flavonoids liposomes LFL were prepared using organic solvent injection method with phospholipids and cholesterol as carriers.

3. The preparation method according to claim 2, characterized in that: The preparation method comprises the following steps: S1. Preparation of Honeysuckle Flavonoid Liposomes LFL Dissolve honeysuckle flavonoids LF in water to obtain an LF aqueous solution, dissolve soybean lecithin and cholesterol in an organic solvent and mix well, inject the organic solvent solution of soybean lecithin and cholesterol into the LF aqueous solution, stir to evaporate the organic solvent, and then ultrasonically break to obtain LF liposomes; the organic solvent is ethanol or ether; S2. Take polyvinyl alcohol (PVA) dissolved in water, add glacial acetic acid and mix well, add chitosan CS and fully dissolve to form a PVA-CS solution. The proportion of each substance used is: PVA: CS: glacial acetic acid: water is 1.5-5 g: 0.3-1 g: 0.4-0.6 mL: 50 mL; LF liposomes, PVA-CS solution and glycerol are mixed in a volume ratio of 4-6: 3-5: 1, and then spread and dried to obtain LFLM; preferably, the proportion of each substance used is: PVA: CS: glacial acetic acid: water is 2-3 g: 0.3-0.7 g: 0.4-0.6 mL: 50 mL.

4. The preparation method according to claim 3, characterized in that: In the step S1, the concentration of the LF aqueous solution is 20-40 mg / mL, and it is preheated to 35-45° C.; the concentration of phospholipids in the organic solvent solution of soybean lecithin and cholesterol is 30-40 mg / mL, the mass ratio of phospholipids to cholesterol is 5-20, and preferably the mass ratio of phospholipids to cholesterol is 14-16. Under stirring conditions, the organic solvent solution of soybean lecithin and cholesterol is slowly injected into the LF aqueous solution with a syringe, wherein the mass ratio of LF to phospholipids is 4-6:1; after stirring and evaporating the organic solvent, an ultrasonic crusher is used to ultrasonicate for 8-20 minutes at 30-50% ultrasonic energy to obtain LF liposomes.

5. The preparation method according to claim 3, characterized in that: In the step S2, polyvinyl alcohol (PVA) is dissolved in hot water at 85-95° C., cooled to room temperature, glacial acetic acid is added and mixed, and chitosan (CS) is added and fully dissolved to form a PVA-CS solution.

6. The preparation method according to claim 3, characterized in that: In step S2, the proportion of the amount of each substance used is: PVA:CS:glacial acetic acid:water is 2.5g:0.5g:0.5mL:50mL; LF liposome, PVA-CS solution and glycerol are mixed in a volume ratio of 5:4:

1.

7. A honeysuckle flavonoid liposome membrane, characterized in that: The preparation method is described in any one of claims 1 to 6.

8. Use of the honeysuckle flavonoid liposome membrane LFLM according to claim 7 in preparing a drug for resisting methicillin-resistant Staphylococcus aureus.

9. The use according to claim 8, characterized in that: Application of honeysuckle flavonoid liposome membrane LFLM combined with VAN in the preparation of drugs for inhibiting methicillin-resistant Staphylococcus aureus MRSA; Preferably, when LFLM and VAN are used together, the mass ratio of LFLM to VAN is 500-5000:1, preferably 500-2000:1 or 800-1500:

1.

10. The use according to claim 8 or 9, characterized in that: LFLM or the combination of LFLM and VAN inhibited the growth, survival and biofilm formation of MRSA.